Menu

SciSparc Ltd. SPRC

Full chart Compare
Set alert

Price alert · SPRC

All alert types
0.42 USD -0.01 (-2.45%)

At closeNov 6, 2026, 6:20 PM EST

0.42 0.00 0.00%

After hours · Nov 6, 6:20 PM ET

0.412 Day range 0.4399
0.4186 52-week range 25.02
YTD
-96.58%
1 year
-98.26%
Market cap
9.66M
Revenue (ttm)
1.75M
EPS (ttm)
248.24
Shares out
10.36M
P/E ratio
0.00
YTD return
-96.58%
1-year return
-98.26%
Volume
68.07K
Avg volume
1.36M
Open
0.43
Previous close
0.4291
Day's range
0.412 – 0.4399
52-week range
0.4186 – 25.02
Beta
1.04

2Y -44.9414 (-99.08%)

0.0000100.0000200.0000Nov 24Feb 25Apr 25Jun 25Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26Oct 260.4186

Key statistics

Enterprise value
4.92K
PEG ratio
0.00
Price / sales
1.38
Price / book
0.12
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-57.40%
Free cash flow
-3.97M
Total cash
2.56M
Total debt
64.00K
Return on equity
-85.91%
Short % of float
0.93%
50-day average
0.23526
200-day average
0.77116

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
SPRC Revenue — quarterly 0
2018-Q4 2018
SPRC Net income — quarterly -4.37M
2018-Q4 2018
SPRC EPS — quarterly 1,375,920.00
2018-Q4 2018

About SciSparc Ltd.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel
Website
scisparc.com

News

Your note

Sign in to keep a note on SPRC — it syncs with the Stock Master app.

Institution ownership

SPRC institution ownership
Holder% heldSharesValueReported
UBS Group AG0.67%69,00616.06KSep 29, 2024
Two Sigma Securities, LLC0.36%37,0828.63KSep 29, 2024
Virtu Financial LLC0.14%14,1063.28KSep 29, 2024
Rhumbline Advisers0.03%3,464806Sep 29, 2024
Morgan Stanley0.00%23855Sep 29, 2024